Navigation Links
24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination

Microbial contamination is the third leading cause of mortality in the U.S., according to the Centers for Disease Control (CDC).

Charleston, SC (PRWEB) March 5, 2010 -- Today’s hospitals have an increasingly dangerous and costly problem. The culprit…Hospital Acquired Infections (HAIs) and they have generated much attention over the last decade. Studies have shown that up to 70% of HAIs are preventable with proper infection control, according to a Nurse Liaison for 24x7 Infection Control, Inc.    

A totally new (to the public) antimicrobial line named Goldshield®™ is a revolutionary product that, through independent studies it was demonstrated to eradicate germs on contact and inhibit their growth. Invented and patented by Emory University, Goldshield®™ is a system of products which includes an antimicrobial that is the first, and only, water-stabilized, non-toxic, non-leaching, environmentally benign solution providing a durable shield against microbial contamination, including mold, mildew and fungi.

Goldshield®™ offers an EPA-registered solution to combat dangerous microbial contamination in virtually every setting including hospitals, outpatient clinics, physicians offices, assisted living facilities, skilled nursing facilities, schools, colleges, athletic clubs, gymnasiums, spas, police departments, emergency medical services, fire departments, correctional institutions, the hospitality industry and commercial laundry facilities, to name a few.

Independent studies conducted at hospitals and universities have demonstrated that Goldshield® is a broad-spectrum bactericide, algaecide and fungicide. In these studies, it has been proven effective against Staphylococcus aureus (Staph), Methicillin-resistant Staphylococcus aureus (MRSA); including HA-MRSA (Healthcare-associated MRSA) and CA-MRSA (community- associated MRSA), Salmonella, E.coli, VRE (Vancomycin-Resistant Enterococci, and other hardy Gram (+) and Gram (-) bacteria. In a recent study in accordance with ASTM (American Society for Testing and Materials) protocols for virucidal efficacy on inanimate surfaces, Goldshield®™ was proven effective against Influenza A as a surrogate for H1N1.

Sharon Harper, an OR nurse and retired, Navy Infection Control Officer, stated, “I have seen the results and can appreciate why Goldshield®™ is so unique. In my opinion, the most exciting use of this new antimicrobial is via a “Bio-Vapor” Steam Cleaning System. This method allows Goldshield®™ to adhere in every ‘nook and cranny’! My mission as the nurse liaison for 24x7 Infection Control, Inc. is to inform government agencies, schools, hospitals, assisted living and long-term care communities that Goldshield®™ is now available.”

The parent company, AP Goldshield LLC is located in the United States, Israel, Asia, and Europe. 24x7 Infection Control, Inc. is an Authorized Distributor for Goldshield®™.

To find out more, please visit

Sharon Harper RN, MSN                                         
Sharon (at) 24x7infectioncontrol (dot) com


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
2. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
3. Computers help chemists fight emerging infections
4. Infection contributes to the high rates of oropharyngeal cancers
5. Jefferson immunology researchers halt lethal rabies infection in brain
6. SIV infection of natural hosts provides new insights into HIV disease complexity
7. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
8. Natural aorta grafts have few side effects for infection-prone patients
9. Common misdiagnosis: most women believe they have a yeast infection when they dont
10. Patient Safety Authority Board of Directors Names Infection Advisory Panel
11. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
Post Your Comments:
Related Image:
24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 
(Date:11/24/2015)... ... 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the ... , FDA has long asserted that design and manufacture of Laboratory Developed Tests ... do not meet the device regulations. , Come up short in an inspection and ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress and ... developer of renewable energy technologies capable of producing commercially useful amounts of thermal ... its WET™ and HHT™ Boiler System reactor core modules were presented to Congress ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... to share their knowledge and experiences at a live taping of the next ... Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University Hotel ...
(Date:11/24/2015)... ... 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse ... of the staff members at their recovery center. The videos highlight some of the ... of the things that make their recovery program so unique. , “Making the decision ...
(Date:11/24/2015)... ... ... Shoulder , LLC launched their Pro Vest, the latest version of their widely popular weight ... under 10 hours. , The campaign, which will continue to run through ... market. , The PRO Vest provides consumers with a less expensive, one-size fits all comfort ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Thanks to a donor ... St. Mary,s Medical Center,s Sister Diane Grassilli Center for ... capabilities in San Francisco . ... friend, stepped forward with a gift of $617,320 that ... Digital Mammography with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, ...
(Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
(Date:11/24/2015)... --> --> ... by Product Type (Bone Graft, Bine Graft Substitute, Platelet Rich ... Lumbar Interbody Fusion), End User, and Geography - Global Forecast ... at $1.90 Billion in 2014 and is expected to reach ... the forecast period of 2015 to 2020. Browse ...
Breaking Medicine Technology: